Use of lecanemab for the treatment of Alzheimer's disease: A systematic review
Abstract Purpose The US Food and Drug Administration authorized lecanemab for the therapeutic use of Alzheimer's disease (AD) in January 2023. To assess the effectiveness and safety of lecanemab in treating AD, we thoroughly examined the studies that are currently accessible. Method Preferred Report...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wiley
2024-06-01
|
| Серии: | Brain and Behavior |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1002/brb3.3592 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|